Development of Eribulin-based Antibody-Drug Conjugates

Time: 4:00 pm
day: Day One

Details:

• Introduction of Eribulin-based ADC BB-1701 and BB-1705
• Discussion of preclinical results of Eribulin-based ADCs
• Progress of BB-1701 phase 1/2 clinical development